Abstract

Provided herein are multivalent signal-regulatory protein α (SIRPα) fusion polypeptides and methods of use thereof. The compositions and methods described herein may be used to treat a variety of diseases or disorders, such as cardiovascular disease.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

A multi-axis fiber Bragg grating sensing system has a plurality of spatially distributed and mechanically isolated three dimensional multi-axis sensing towers, each having a plurality of connected nonparallel sensing pillars having a straight portion of a length and straightness to support a fiber Bragg grating and connected to at least one other of the three dimensional multi-axis sensing towers via a curved portion having a curvature radius equal to the minimum bend radius of an affixed optical fiber. The optical fiber has a plurality of fiber Bragg gratings and is affixed to each of the dimensional multi-axis sensing towers wherein a fiber Bragg grating is positioned along a straight portion of a sensing pillar of each of the towers. An interrogator captures and measures wavelength data from the fiber Bragg gratings for measuring multi-axis force information applied to each of the three dimensional multi-axis sensing towers.

IPC Classes  ?

• G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis

Abstract

Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLPIRA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/26 - Glucagons
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis

Abstract

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The disclosure relates to compounds that act as inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents

Abstract

A microfluidic sample preparation device, a fully automated analysis pipeline, a method of conducting an immune cell activation and analytical test.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present disclosure provides methods for improving cardiac dysfunction in a subject by inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH), e.g., by administering a small molecule drug, thereby increasing prostaglandin levels, e.g., prostaglandin E2 (PGE2) levels, in the subject.

IPC Classes  ?

• A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• G01N 33/88 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving prostaglandins
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases
• A61P 3/00 - Drugs for disorders of the metabolism
• A61K 38/46 - Hydrolases (3)

Abstract

A system for creating an endoluminal valve from a blood vessel wall, includes: a tubular assembly having a longitudinal axis, a proximal end, a distal portion with a distal end, and a first lumen extending from the proximal end to a distal port located proximate the distal portion, the distal port located along the longitudinal axis, the distal portion having a supporting surface on a same side of the tubular assembly as the distal port, the supporting surface extending in a longitudinal direction and offset from a surface of the tubular assembly proximal the distal port and configured to contact the blood vessel wall; and a tissue dissection probe disposed within the first lumen, the tissue dissection probe having a fluid delivery lumen extending to a fluid delivery port located at a distal end of the tissue dissection probe, the tissue dissection probe configured to be inserted into the blood vessel wall.

IPC Classes  ?

• A61B 17/3203 - Fluid jet cutting instruments
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
• A61B 17/08 - Wound clamps
• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
• A61B 17/295 - Forceps for use in minimally invasive surgery combined with cutting implements
• A61B 17/30 - Surgical pincettes, i.e. surgical tweezers
• A61B 17/32 - Surgical cutting instruments
• A61B 17/3207 - Atherectomy devices
• A61B 17/3209 - Incision instruments
• A61B 17/34 - TrocarsPuncturing needles
• A61F 2/24 - Heart valves

Abstract

Processes to spatially align single cells to yield a specimen map with single cell resolution are provided. Methods can perform spatial omics on a specimen to yield spatial omics data. The spatial omics data can be used in combination with single cell omics data to assign single cells to spatial coordinates to yield a resolved specimen map.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G16B 40/20 - Supervised data analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06T 7/00 - Image analysis

Abstract

Provided are methods of analyzing target nucleic acids, the methods comprising, using the target nucleic acids as reagents and reporters as substrates, assaying enzyme kinetic parameters of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) endonucleases comprising guide RNAs (gRNAs) that hybridize with reference nucleic acids. In certain aspects, certain such methods comprise comparing a sequence of a target nucleic acid with a sequence of a reference nucleic acid. In some embodiments, such comparison is based on the rates of cleavage of the reporters at plurality of concentrations of the reporters. The kinetic parameters can also be the Michaelis-Menten constant (KM), the apparent turnover rate (K*cat), and/or the apparent catalytic efficiency (K*cat/KM). Kits for performing the methods of the disclosure are also provided.

IPC Classes  ?

• C12Q 1/6823 - Release of bound markers
• C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]

Abstract

Cytokine adaptors, compositions comprising cytokine adaptors, and methods of use thereof, are provided. Cytokine adaptors are bi-specific binding proteins that alter the specificity of a receptor/ligand interaction. The adaptors generally act by simultaneously binding to a target protein and a receptor to drive a context-dependent response.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells with a combination of antibodies specific for CD117, and agents that modulate immunoregulatory signaling pathways, e.g. agonists of immune costimulatory molecules, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment, even in immunocompetent recipients.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Compositions and methods are provided for genetically modifying a cell to introduce both a gene knockin and a gene knockout. The subject methods use a donor polynucleotide comprising a gene knockin sequence and a knockout guide RNA sequence. Transcription of the donor polynucleotide, after integration of the donor polynucleotide into the genome, produces a mature mRNA sequence comprising the knockout guide RNA. An RNA-guided nuclease is used to excise the knockout guide RNA from the mRNA transcript, which then guides the RNA-guided nuclease to a second target locus where the RNA-guided nuclease creates a double stranded DNA break, resulting in gene knockout at the second target locus. Only cells with the gene knockin are able to express the mRNA containing the knockout guide RNA so that the gene knockin at the first genomic target locus and the subsequent gene knockout at the second genomic target locus are linked.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 9/22 - Ribonucleases
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]

Abstract

Compositions and methods are provided for assembling a multi-module gene editing construct. Methods of producing a combinatorial library comprising a plurality of multi-module gene editing constructs are also provided. The subject methods enable any type of genetic modification to be tested in combination with other genetic modifications.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 9/14 - Hydrolases (3.)
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

Compositions and methods are provided for multiplexed screening of chimeric antigen receptor (CAR)-T cells. The subject methods allow engineered T cells from multiple donors to be pooled and tested simultaneously. Pooling of T cells from multiple subjects for screening decreases the cost of cell therapy development and makes pre-clinical development work for autologous and allogeneic engineered T cell therapies more efficient.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

Provided herein are compositions comprising T cells modified to overexpress FOXO1 and methods of use thereof. Methods are provided to treat a disease or disorder in a subject comprising administration of the modified T cells. Also provided are methods for preventing exhaustion of engineered T cells comprising introducing a nucleic acid that overexpresses FOXO1 into the T cells.

IPC Classes  ?

• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/42 - Cancer antigens
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 15/86 - Viral vectors

Abstract

The disclosure is directed to methods and compositions for screening a library of aptamers for aptamers having a binding affinity to a target molecule. The methods and compositions described herein utilize a throughput approach that is able to simultaneously measure binding affinity and link the binding affinity to the identity (e.g., sequence) of the aptamer.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding

Abstract

In certain examples, methods, apparatuses and semiconductor-related structures are directed to nighttime-like electrical power generation by use of a spectro-angular selective emitter as an optimal radiative cooler and a thermoelectric power generator (TEG) having a hot side and a cold side. The cold side may be coupled to the spectro-angular selective emitter which is directed to or facing an atmosphere characterized by an absence of solar light. Power may be generated via the TEG based on energy directed from the spectro-angular selective emitter and by controlling or limiting ability of the spectro-angular selective emitter to absorb heat power at frequencies and/or angles where emission of the atmosphere is dominant.

IPC Classes  ?

• H10N 10/17 - Thermoelectric devices comprising a junction of dissimilar materials, i.e. devices exhibiting Seebeck or Peltier effects operating with only the Peltier or Seebeck effects characterised by the structure or configuration of the cell or thermocouple forming the device

Abstract

Systems, methods, and other embodiments described herein relate to an interface for training a visuomotor policy to be device agnostic and controlling a robotic device using the visuomotor policy. In one embodiment, a method includes collecting sensor data about a robotic manipulator within an environment. The method includes pre-processing the sensor data to compensate for an observation latency of at least one sensor associated with the robotic manipulator. The method includes generating actions for the robotic manipulator to perform a task according to the sensor data and a visuomotor policy. The method includes controlling the robotic manipulator, including compensating for execution latency of the robotic manipulator in performing the actions.

IPC Classes  ?

• B25J 9/16 - Programme controls
• B25J 19/02 - Sensing devices

Abstract

The present disclosure provides a method of producing human sensory organoids in vitro. The present disclosure provides a method of producing human dorsal hindbrain/cervical spinal cord organoids in vitro. The present disclosure provides a method of producing human ascending somatosensory assembloids in vitro. The present disclosure also provides a method of determining the effectiveness of a candidate agent on a human ascending somatosensory pathway assembloid. Also provided are human sensory organoids, human dorsal hindbrain/cervical spinal cord organoids, and human ascending somatosensory assembloids.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Compositions and methods are provided for genetically modifying a T cell to express a chimeric antigen receptor (CAR) with knockout of an endogenous T cell receptor (TCR). The subject methods utilize a donor polynucleotide encoding a CAR that is integrated into an intron of a TCR gene. By knocking in a synthetic exon expressing the CAR into an intron, the successfully edited T cells produce a mature mRNA with a nucleotide sequence encoding the CAR spliced in between the exon(s) encoding the TCR protein, resulting in expression of the CAR and knockout of the TCR. In contrast, the unsuccessfully edited T cells retain expression of their TCR. The T cell population can be enriched for successfully edited TCR negative T cells expressing the CAR by using negative selection to remove unsuccessfully edited TCR positive T cells with binding agents that bind to the TCR marker.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 19/00 - Hybrid peptides
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]

Abstract

Composition and methods are provided for the treatment of a mammalian subject for axonopathies by increasing activity of axon regeneration-associated gene (RAG) as identified herein, which include without limitation ANXA2, TPA, GSN, VIM, MPP1, ILK, ECM1, CALM1, AND ACAA2. These genes are shown to significantly promote axon regeneration, dramatically protects retinal ganglion cells and optic nerves, and preserve visual function in a clinically relevant model of glaucoma. A therapeutic entity may comprise, for example, a RAG protein, a gene therapy vector comprising a RAG coding sequence, a small molecule that enhances RAG activity, and the like.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/49 - UrokinaseTissue plasminogen activator
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/864 - Parvoviral vectors

Abstract

The present disclosure provides recombinant polypeptides containing a payload sequence and one or more 3'-untranslated region (3'-UTR) sequences downstream of and operably linked to the payload sequence. The one or more 3'-UTR sequences, or RNA transcripts thereof, respond to an intracellular signal by modulating the translation, transcription, and/or stability of the payload sequence or an RNA transcript thereof. The disclosure also provides DNA constructs, vectors, cells, and systems including the provided recombinant polypeptides, as well as methods for modifying cells and/or preventing or treating a disease by using the provided materials.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Abstract

Disclosed herein are compositions comprising a polymer and a metabolic inhibitor, as well as a method of using the composition to modulate an immune response. The composition may be produced in the form of a synthetic tissue for provision in a subject. The composition or synthetic tissue may further comprise additional therapeutic agents.

IPC Classes  ?

• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin

Abstract

Methods of deconvolving a feature profile of a physical system are provided herein. The present method may include: optimizing a regression between a) a feature profile of a first plurality of distinct components and b) a reference matrix of feature signatures for a second plurality of distinct components, wherein the feature profile is modeled as a linear combination of the reference matrix, and wherein the optimizing includes solving a set of regression coefficients of the regression, wherein the solution minimizes 1) a linear loss function and 2) an L2-norm penalty function; and estimating the fractional representation of one or more distinct components among the second plurality of distinct components present in the sample based on the set of regression coefficients. Systems and computer readable media for performing the subject methods are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
• G16C 20/20 - Identification of molecular entities, parts thereof or of chemical compositions

Abstract

Imaging devices, systems, and methods are provided for imaging using narrow bands of short wavelength infrared (SWIR) light, e.g., to image at water absorption wavelength and/or to image through blood. In one example, an imaging device is provided for imaging during a medical procedure that includes a proximal end, a distal end sized for introduction into a subject's body, and an imaging element carried by the distal end, a light source coupled to the imaging device to deliver one or both of narrow band short wavelength infrared (SWIR) light and visible light, and a camera for acquiring images via the imaging element.

IPC Classes  ?

• H04N 23/50 - Constructional details
• G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes
• H04N 23/55 - Optical parts specially adapted for electronic image sensorsMounting thereof
• H04N 23/56 - Cameras or camera modules comprising electronic image sensorsControl thereof provided with illuminating means
• H04N 23/63 - Control of cameras or camera modules by using electronic viewfinders

Abstract

Provided herein are methods for producing a cultured tissue that mimics a natural tissue or organ. In some embodiments, the methods comprise culturing cells in a three-dimensional (3D) pattern on a scaffold, and applying an exogenous force to the cells while the cells are cultured. The applied exogenous force induces the cultured cells to form a cultured tissue that mimics the 3D cellular pattern and biomechanics of the natural tissue or organ. Also provided herein are bioreactors for producing a cultured tissue that mimics a natural tissue or organ. In certain embodiments, the bioreactors comprise: a scaffold for culturing cells in 3D pattern, and an exogenous force applicator to exert an exogenous force to the cells cultured in the 3D pattern. Additional embodiments provide cultured tissues that mimic natural tissues or organs as produced according to the methods disclosed herein.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/07 - Animal cells or tissues

Abstract

Methods are provided for the preconditioning, conditioning, or rehabilitation of marginal organs to be used for organ or organ-derived cell transplantation. The methods of the present disclosure contact the marginal organs with a medium or perfusate comprising an effective dose of a Wnt agent. The Wnt agent reduces apoptosis of the cells in the marginal organ while also activating stem cells present in the marginal organ to promote repair, reconditioning, and/or regeneration of the marginal organ. Preconditioning or conditioning of the marginal organ with a Wnt agent reduces the risk of reperfusion injury. In some embodiments, preconditioning of the marginal organ reduces the risk of graft rejection when transplanted into an individual in need thereof.

IPC Classes  ?

• A01N 1/10 - Preservation of living parts
• A01N 1/143 - Apparatus for organ perfusion
• A01N 1/122 - Preservation or perfusion media

Abstract

Provided are recombinant viral genomes. The viral genomes find use in a variety of contexts including for the production of viruses effective in inducing death of cells exhibiting a signal specific to a disease or disorder in a subject, where the viral life cycle is dependent upon the signal specific to the disease or disorder. According to some embodiments, the viral genomes comprise one or more transcription units comprising a sequence encoding a first fusion protein comprising a protease and a first binding domain that binds to a first target, and a sequence encoding a second fusion protein comprising a membrane-targeting signal, a second binding domain that binds to a second target, a cleavable substrate for the protease, and either a transcriptional effector protein or viral protein encoded by a viral gene deleted in the viral genome. Also provided are related cells, virions, pharmaceutical compositions and methods of use.

IPC Classes  ?

• A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus
• A61K 35/761 - Adenovirus
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

A tracheal intubation device includes a housing configured to be inserted into a subject. A first everting vine robot is coupled to the housing and configured to extend from the housing, when inserted into the subject, to the back of a laryngopharynx of the subject when actuated. A second everting vine robot is coupled to the first everting vine robot and configured to extend from the actuated primary vine robot into a trachea of the subject when actuated. An airflow lumen is provided by the housing, the first everting vine robot, and the second everting vine robot from outside a body of the subject to the trachea of the subject.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes
• A61M 16/10 - Preparation of respiratory gases or vapours
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters

Abstract

Disclosed herein are compounds that inhibit leucine-rich repeat kinase 2 (LRRK2), pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., in a method of treating a disorder that derives in full or in part from LRRK2 kinase activity, such as neurodegenerative diseases, immune-mediated diseases, and forms of cancer.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/33 - Heterocyclic compounds

Abstract

Anomalously large charge storage, charge release and/or charge transport is provided in room temperature MIS (Metal-Insulator-Semiconductor) capacitive structures. These parameters can be 10× or more (often orders of magnitude more) than what would be expected from the classical capacitance of the structure. This anomalous behavior is attributed to topological states formed in the MIS structure under bias when there are both in-plane and out of plane components of the biasing electric field. One signature of this new physical effect is an inverse dependence of maximum current density on area.

IPC Classes  ?

• H10D 1/66 - Conductor-insulator-semiconductor capacitors, e.g. MOS capacitors
• H10D 1/00 - Resistors, capacitors or inductors

Abstract

The present disclosure is directed toward systems and methods for performing spectral imaging. Embodiments include a spectral imager having spectral router that is formed on a light-detection layer that includes a plurality of photodetectors. The spectral router has a structure that includes a first plurality of scatterers that is arranged within the spectral router in a first arrangement. The spectral router also includes a first material having a first dielectric constant. Each scatterer includes at least a second material having a second dielectric constant that is different than the first dielectric constant.

Abstract

Aspects of the present disclosure include methods for making a conductive pyrolytic carbon microstructure. Methods according to certain embodiments include irradiating a polymerizable composition positioned between a build elevator and a build surface to generate a polymerizable composition having a first polymerized region of the polymerizable composition in contact with the build elevator and a first non-polymerized region of the polymerizable composition in contact with the build surface, displacing the build elevator away from the build surface, irradiating the first non-polymerized region of the polymerizable composition to generate a second polymerized region of the polymerizable composition in contact with the first polymerized region and a second non-polymerized region in contact with the build surface, repeating this in a manner sufficient to generate a polymeric microstructure, contacting the polymeric microstructure with a carbon precursor component (e.g., incorporating a carbon precursor component into the polymeric microstructure) and pyrolyzing the polymeric microstructure to generate a conductive pyrolytic carbon microstructure with a conductive component positioned therein. In some instances, the pyrolytic carbon microstructure is an interpenetrating network that forms a homogeneous pyrolytic carbon material. Conductive pyrolytic carbon microstructures having a conductive component positioned within prepared by the subject methods are also disclosed. Microelectrodes having conductive pyrolytic carbon microstructures (e.g., where the conductive pyrolytic carbon microstructures are positioned on a substrate) are also provided.

IPC Classes  ?

• C01B 32/158 - Carbon nanotubes
• C01B 32/17 - Purification
• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 80/00 - Products made by additive manufacturing
• B33Y 40/20 - Post-treatment, e.g. curing, coating or polishing
• C08L 35/02 - Homopolymers or copolymers of esters
• C08F 22/10 - Esters

Abstract

In certain examples, methods and semiconductor structures are directed to a semiconductor device having a circuit that includes an active region (e.g., a channel region of a transistor) and having a poly crystalline-diamond-based thermal field plate (“TFP”). The TFP, or a first portion thereof, is oriented over or under the active region. Further, the first portion is located in proximity to the active region for passing heat away from the active region, and includes a layer of poly crystalline-diamond grains with an average grain width dimension and an average thickness dimension, wherein the average grain width dimension and the average thickness dimension characterize the poly crystalline-diamond grains as being more isotropic than columnar. With the first portion, or the entire TFP, being in close proximity of the channel region, during operation of the circuit, the TFP passes heat away from the channel region to maintain a relatively low-temperature circuit.

IPC Classes  ?

• H01L 23/373 - Cooling facilitated by selection of materials for the device

Abstract

Thrombectomy devices are provided that include an elongated shaft including a proximal end coupled to a motor configured to spin the shaft, a distal end sized for introduction into a body lumen of a patient, and a longitudinal axis extending therebetween, the shaft configured to rotate about the axis, and a spinner tip on the distal end configured to generate localized suction adjacent the distal end when the shaft rotates. The spinner tip may be introduced into or provided within a lumen of a catheter including an outlet in a distal end thereof that is positioned adjacent a clot. With the spinner tip positioned adjacent the outlet, e.g., within the catheter lumen, the motor may be activated to generate localized suction, e.g., to dissolve the clot, reduce clot size, and/or prevent fragmentation of the clot.

IPC Classes  ?

• A61B 17/3207 - Atherectomy devices

Abstract

Thrombectomy devices are provided that include an aspiration catheter and a spinner device movable axially within the aspiration catheter. The spinner device includes a rotation shaft including a proximal end coupled to a motor configured to spin the shaft, a distal end carrying a spinner head movable axially within the aspiration catheter and configured to generate localized suction when the shaft rotates. The spinner device may also include an outer sleeve surrounding the rotation shaft at least partially along its length to protect the aspiration catheter. The spinner device and aspiration catheter include cooperating stops that limit advancement of the spinner device to prevent the spinner head from being exposed beyond a short distance beyond a distal end of the aspiration catheter, e.g., a wing-stopper provided on one of the rotation shaft, spinner head, and outer sleeve, and a corresponding ring within the distal end of the aspiration catheter.

IPC Classes  ?

• A61B 17/3207 - Atherectomy devices
• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for

Abstract

High affinity SIRP-α reagent are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for CD47 relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity SIRPα reagent, which blocks the physiological binding interaction between SIRPα and its ligand CD47.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Systems and methods for predictive glucose in accordance with embodiments of the invention are illustrated. One embodiment includes glucose management device, including a brain signal recorder, and a controller, including a processor, and a memory, the memory containing a glucose monitoring application configured to direct the processor to record a brain activity signal of a user's brain using the brain signal recorder, and decode the brain activity signal to predict future glucose levels of the patient.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value

Abstract

In certain specific examples, methods and semiconductor structures are directed to a semiconductor device developed based on a two-step annealing process. In the first step, diffusion doping is used to apply (which may include, e.g., depositing a doped layer) a dopant towards a target region of a wafer or a transistor-device layer by effecting an early anneal while a thin layer of dopant-inclusive material is formed on, or spun onto, the target region. This may be implemented to provide a diffusion-doped dopant profile into the target region that is characterized in terms of flatness and depth. The second step involves providing a later anneal, while the target region is exposed to an ambient gas, to alter the dopant profile by increasing flatness and depth aspects of dopant profile.

IPC Classes  ?

• H01L 21/20 - Deposition of semiconductor materials on a substrate, e.g. epitaxial growth
• H01L 21/203 - Deposition of semiconductor materials on a substrate, e.g. epitaxial growth using physical deposition, e.g. vacuum deposition, sputtering
• H01L 21/205 - Deposition of semiconductor materials on a substrate, e.g. epitaxial growth using reduction or decomposition of a gaseous compound yielding a solid condensate, i.e. chemical deposition
• H01L 21/225 - Diffusion of impurity materials, e.g. doping materials, electrode materials, into, or out of, a semiconductor body, or between semiconductor regionsRedistribution of impurity materials, e.g. without introduction or removal of further dopant using diffusion into, or out of, a solid from or into a solid phase, e.g. a doped oxide layer
• H01L 21/383 - Diffusion of impurity materials, e.g. doping materials, electrode materials, into, or out of, a semiconductor body, or between semiconductor regions using diffusion into, or out of, a solid from or into a gaseous phase
• H10D 62/17 - Semiconductor regions connected to electrodes not carrying current to be rectified, amplified or switched, e.g. channel regions
• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
• H01L 21/22 - Diffusion of impurity materials, e.g. doping materials, electrode materials, into, or out of, a semiconductor body, or between semiconductor regionsRedistribution of impurity materials, e.g. without introduction or removal of further dopant
• H01L 21/38 - Diffusion of impurity materials, e.g. doping materials, electrode materials, into, or out of, a semiconductor body, or between semiconductor regions
• H10D 62/10 - Shapes, relative sizes or dispositions of the regions of the semiconductor bodiesShapes of the semiconductor bodies
• H10D 62/13 - Semiconductor regions connected to electrodes carrying current to be rectified, amplified or switched, e.g. source or drain regions

Abstract

Methods for the early detection of subjects at risk of developing rheumatoid arthritis, and subjects having early rheumatoid arthritis thus allowing for early intervention.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

The disclosure relates to pharmaceutical composition comprising dopamine antagonists and methods of using the same to treat pain, prevent drug liking and opioid addiction.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/33 - Heterocyclic compounds

Abstract

Disclosed is a method to achieve digital quantification of DNA (i.e., counting differences between identical sequences) using direct shotgun sequencing followed by mapping to the chromosome of origin and enumeration of fragments per chromosome. The preferred method uses massively parallel sequencing, which can produce tens of millions of short sequence tags in a single run and enabling a sampling that can be statistically evaluated. By counting the number of sequence tags mapped to a predefined window in each chromosome, the over- or under-representation of any chromosome in maternal plasma DNA contributed by an aneuploid fetus can be detected. This method does not require the differentiation of fetal versus maternal DNA. The median count of autosomal values is used as a normalization constant to account for differences in total number of sequence tags is used for comparison between samples and between chromosomes.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6869 - Methods for sequencing
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

Devices, systems, and methods for a wearable, real-time cognitive behavioral detection and/or therapy device for detecting impulsivity states of a user, and for providing alerts to the patient and/or a patient-identified network of persons, of an impending impulsivity state. The device utilizes a combination of wearable, non-invasive, sensors configured to be worn by a user and to detect electrophysiology signals and/or psychophysiological signals of the user. The sensors output respective sensor signals corresponding to the electrophysiology signals and psychophysiological signals and transmit the respective sensor signals to a computing device. The computing device has a software application which programs the computing device to process the sensor signals and provide informational and/or therapeutic information regarding an impulsivity state of the user. The device may also include a system for delivering electrical stimulation directly to the user in response to the impulsivity state detected by the device.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

Provided are methods of differentiating ventral pharyngeal pouch endoderm (PPEv) cells to thymic epithelial progenitor cells (TEPCs). Such methods comprise culturing PPEv cells in a TEPC differentiation medium comprising an inflammasome activator, a nuclear factor-kappa B (NF-κB)/Toll-like receptor (TLR) signaling activator, a TLR signaling activator, a tumor necrosis factor (TNF) signaling activator, or any combination thereof. Also provided are methods of producing mature thymic epithelial progenitor cells (matTEPCs). Such methods comprise culturing TEPCs in a TEPC maturation medium comprising an inflammasome activator, a nuclear factor-kappa B (NF-κB)/Toll-like receptor (TLR) signaling activator, a TLR signaling activator, a tumor necrosis factor (TNF) signaling activator, or any combination thereof. TEPCs and matTEPCs produced according to the methods of the present disclosure are also provided, as are compositions comprising the TEPCs and matTEPCs. Methods of using the TEPCs and matTEPCs, e.g., for therapeutic purposes in athymic or hypothymic subjects, are also provided.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/26 - LymphLymph nodesThymusSpleenSplenocytesThymocytes
• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor

Abstract

Water-soluble conjugates of verteporfin are provided, which find therapeutic use, including by topical administration. Also provided are liposomal verteporfin formulations, which may be admixed with biomolecules such as hyaluronic acid.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• A61K 9/51 - Nanocapsules
• A61P 27/02 - Ophthalmic agents

Abstract

The disclosure provides methods for preventing unintended concatemeric insertions arising from CRISPR/AAV-mediated genetic modifications to increase editing efficiency, decrease off-target effects, and improve on-target fidelity. Also provided are digital droplet PCR-based methods for evaluating complex genotypes and detecting unintended concatemeric insertions.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/864 - Parvoviral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 35/76 - VirusesSubviral particlesBacteriophages

Abstract

Switchable and/or tunable surface topography is provided using a polymer having a crosslinking pattern formed within it. In operation the polymer is exposed to a liquid and it is switched or tuned between its various states by changing properties of the liquid. One of these states is a reference or " flat" state where the polymer thickness is substantially constant and the pattern is not apparent. In other states, the polymer swells in a pattern that corresponds ( inversely) to the crosslinking pattern. The less crosslinking there is at a point in the polymer, the more swelling there is at that point. The top and/or bottom surfaces of the polymer can be coated with metal to enhance the optical effects of these controllable thickness changes. By stacking such polymer layers, various combined functions are provided, such as independent control of texture and color.

IPC Classes  ?

• G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
• G02B 5/30 - Polarising elements
• G02B 6/35 - Optical coupling means having switching means
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
• G02B 1/08 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of polarising materials
• G02B 6/10 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
• C08K 5/00 - Use of organic ingredients

Abstract

The invention provides a human cell-based delivery system for performing in vivo genetic modifications. The human cells are engineered to express and secrete one or more components of a gene editing technology which are taken up by target cells in vivo such that the target cells are genetically modified.

IPC Classes  ?

• C12N 7/02 - Recovery or purification
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/15 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/074 - Adult stem cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus
• A61K 38/46 - Hydrolases (3)
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases

Abstract

Systems and methods for enhancing yield of synthesis and molecular processing of nucleic acid species are described. Nucleic acid species can be synthesized or molecularly processed in batches or pools. The nucleic acid species within a batch or pool have been determined to have a similar yield efficiency with the other nucleic acid species within its batch or pool.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 40/20 - Supervised data analysis
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Provided are methods of treating pain in a subject in need thereof. The methods comprise administering to the subject a senolytic in an amount effective to treat the pain. According to some embodiments, the senolytic is administered as the only active agent to treat the pain. In other embodiments, the senolytic is administered in combination with a second active agent (e.g., a second senolytic or non-senolytic active agent) to treat the pain. Non-limiting examples of pain treatable by the methods include chronic inflammatory pain, surgery-induced pain, complex regional pain syndrome (CRPS) type 1 or type 2, neuropathic pain, diabetic peripheral neuropathy, and age-related pain. Also provided are kits that find use in practicing the methods of the present disclosure.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

A force sensor includes one or more upconverting nanoparticles. Each of the one or more upconverting nanoparticles include an emitter. The force sensor also includes a polymeric host at least partially around the one or more upconverting nanoparticles. The polymeric host exhibits electronic-vibrational coupling with the emitter in a stress dependent manner.

IPC Classes  ?

• G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis
• G01B 11/16 - Measuring arrangements characterised by the use of optical techniques for measuring the deformation in a solid, e.g. optical strain gauge
• G01N 21/64 - FluorescencePhosphorescence
• G01L 5/18 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring ratios of force

Abstract

Electrospun nanofiber membranes are provided. The membranes are electrospun from a suitable biocompatible and biodegradable biopolymer, e.g. gelatin, collagen, etc., to generate a membrane, which is then cross-linked. The membrane may be seeded with cells. The compositions find use tissue regeneration, particularly in repair, regeneration, and/or reconstruction of lamellar or partial defects of wounded corneal tissue.

IPC Classes  ?

• D01D 5/00 - Formation of filaments, threads, or the like
• A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes
• A61L 27/14 - Macromolecular materials

Abstract

In one aspect, the disclosure relates to a method for oxidizing alkanes to produce industrially useful solvents and other compounds. In a further aspect, the method includes the steps of contacting an alkane or mixture of alkanes with a core-shell nanoparticle and an oxidant to produce a mixture and then irradiating the mixture with UV and/or visible light. The methods are selective for desired products and do not produce overoxidized species such as, for example, carbon dioxide. In a still further aspect, the methods are scalable and can be conducted for a short time under relatively mild conditions. In an aspect, the core-shell nanoparticle includes a metal-oxide containing semiconductor core, an amorphous, radiation transparent shell, and optional metal nanoparticle dopants in the shell. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

IPC Classes  ?

• C07C 51/275 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation with oxides of nitrogen or nitrogen-containing mineral acids of hydrocarbyl groups
• B01J 21/06 - Silicon, titanium, zirconium or hafniumOxides or hydroxides thereof
• B01J 21/08 - Silica
• B01J 23/52 - Gold
• B01J 35/30 - Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
• B01J 35/39 - Photocatalytic properties
• B01J 37/00 - Processes, in general, for preparing catalystsProcesses, in general, for activation of catalysts
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/04 - Mixing
• B01J 37/06 - Washing
• B01J 37/08 - Heat treatment
• B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves
• C07C 29/48 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups
• C07C 29/50 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups with molecular oxygen only
• C07C 45/28 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation of —CHx-moieties
• C07C 45/34 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation with molecular oxygen of CHx-moieties in unsaturated compounds
• C07C 51/25 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation with molecular oxygen of unsaturated compounds containing no six-membered aromatic ring
• C07C 407/00 - Preparation of peroxy compounds

Abstract

Compositions and methods are provided to enrich for DNA corresponding to a genome of interest, e.g. by species, clade, or strain of origin, from a mixed population of nucleic acid sequences. The methods may further comprise identification of the genomic sequences of interest, e.g. identifying the species, clade, strain, etc. of origin.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
• C12Q 1/6869 - Methods for sequencing

Abstract

A pneumatic haptic sleeve is provided which is knit in one piece with a top side and a bottom side. The top side has a relatively soft and stiff stiffness areas. The soft areas are of increasing stiffness, where the softest is right beneath pneumatic actuators and allows for actuator deformation. The high stiff area is above and around the pneumatic actuators. The pneumatic actuators fit within the knitted sleeve such that the top side of the pneumatic actuator matches up with the high stiffness area, and the bottom side of the pneumatic actuator matches up with the low stiffness area. The pneumatic actuator has two states: actuated and non-actuated. The pneumatic haptic sleeve is portable, self-contained, and comfortable to wear, thereby promoting extended wearability and more consistent use in mediated social touch applications.

IPC Classes  ?

• G08B 6/00 - Tactile signalling systems, e.g. personal calling systems

Abstract

Integrated systems and methods are provided for non-photosynthetic microbial conversion of low concentrations of dissolved inorganic carbon (DIC), including from alkaline solutions, to capture, concentrate, and store CO2 as methane (CH4) biogas or any other reduced organic compound. The methods allow CO2 capture and conversion, and can provide a source of hydrocarbons for synthesis, energy generation, carbon storage, and the like. The methods disclosed herein produce end products at high selectivity relative to chemical catalysis systems.

IPC Classes  ?

• C12P 5/02 - Preparation of hydrocarbons acyclic
• C02F 3/34 - Biological treatment of water, waste water, or sewage characterised by the microorganisms used
• C02F 101/10 - Inorganic compounds
• C02F 103/08 - Seawater, e.g. for desalination
• C12M 1/107 - Apparatus for enzymology or microbiology with means for collecting fermentation gases, e.g. methane
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The present disclosure provides a barcode and print approach that links particular members of pooled sequenced libraries to specific protein variants that interact with the particular library members; and devices that allow such library-on library measurements.

IPC Classes  ?

• C12Q 1/6813 - Hybridisation assays
• C12Q 1/6869 - Methods for sequencing
• C40B 60/14 - Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

A sensor system includes a ranged sensor that generates time-series data indicating positions of objects in an environment, and at least one processor that receives the time-series data generated by the ranged sensor, encodes the time-series data into edge embeddings with an encoder, and computes edge features and edge logits of the objects in the environment, represented in a latent space, based on the edge embeddings. The at least one processor also disentangles the edge features in the latent space, and generates a representation of time-invariant latent characteristics of interactions between the edge features in the latent space.

IPC Classes  ?

• G01S 7/48 - Details of systems according to groups , , of systems according to group
• G01S 17/06 - Systems determining position data of a target
• G01S 17/89 - Lidar systems, specially adapted for specific applications for mapping or imaging

Abstract

A chemical reactor for inductive heating has a non-conductive reactor wall (104) defining an interior (106) of the reactor, a conductive electromagnetic metamaterial susceptor (102) having an open cell 3D lattice structure distributed throughout a volumetric region within the interior of the reactor, electromagnetic coils (100) surrounding the susceptor, and a power supply (116) connected to the electromagnetic coils and adapted to produce AC electrical power at a predetermined operating frequency, thereby generating an electromagnetic field having a predetermined wavelength causing inductive heating of the susceptor. The susceptor has a predetermined effective AC conductivity response Gefr as a predetermined function of position within the volumetric region at the predetermined operating frequency.

IPC Classes  ?

• B01J 19/32 - Packing elements in the form of grids or built-up elements for forming a unit or module inside the apparatus for mass or heat transfer
• B01J 6/00 - CalciningFusing

Abstract

Provided are methods of generating cells that produce monoclonal antibodies that specifically bind domain 2 of a human lymphocyte activation gene-3 (LAG-3) polypeptide. The methods comprise immunizing a non-human animal with an immunogen comprising domain 2 of a human LAG-3 polypeptide and isolating monoclonal antibody-producing cells from the non-human animal, wherein the monoclonal antibody-producing cells produce monoclonal antibodies that specifically bind the immunogen. Such methods further comprise screening the monoclonal antibody-producing cells for cells that produce monoclonal antibodies that specifically bind domain 2 of human LAG-3. Also provided are in vitro methods of identifying a polypeptide that specifically binds domain 2 of a human LAG-3 polypeptide, as well as in silico methods of identifying an agent as a candidate human LAG-3 dimerization disrupting agent. Antibodies, polypeptides and agents identified according to the methods of the present disclosure are also provided.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Methods of promoting healing of a wound in a dermal location of a subject are provided. Aspects of the methods may include administering an effective amount of a Piezo inhibitor composition to the wound to promote healing of the wound, e.g., by reducing transition of adipocytes to fibroblasts in the wound. Also provided are methods of preventing or reversing scarring during healing of a wound in a subject. Aspects of the methods may include forming a wound in a dermal location of a subject and administering an effective amount of a Piezo inhibitor composition to the wound to promote regenerative healing or regenerative remodeling of the wound. Also provided are methods of ameliorating, e.g., reducing or inhibiting, organ fibrosis, e.g., liver fibrosis, heart fibrosis, inflammatory bowel fibrosis, muscle fibrosis, kidney fibrosis, etc., in a subject by administering to the subject an effective amount of a Piezo inhibitor composition. Also provided are kits including an amount of a Piezo inhibitor composition.

IPC Classes  ?

• A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The present disclosure generally relates to, inter alia, recombinant immune cells that have been engineered to express reduced levels of one or more subunits of the mediator complex, and particularly relate to engineered immune cells exhibiting enhanced effector functions. Also provided are methods for generating engineered immune cells with enhanced effector function, pharmaceutical compositions the same, as well as methods and kits for the prevention and/or treatment of a health condition in subjects in need thereof.

IPC Classes  ?

• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• A61P 35/00 - Antineoplastic agents
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

Sensors described in this disclosure have unexpectedly improved stability in challenging environments, including whole blood. The increased stability is at least partly result of a polymer coating that covers a nanoporous layer. The polymer coating allows analytes to travel through to recognition elements within a nanopore in the nanoporous layer. The polymer coating and the nanopore reduce or eliminate the travel of interferents to degrade or foul the recognition elements. The nanoporous layer may define a nanopore or plurality of nanopores. The recognition element may be in contact with the nanoporous layer and disposed in the nanopore. The recognition element may be configured to bind to the analyte to form a complex that sends a signal. Systems, methods of making the systems, and methods of using the systems are described.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6825 - Nucleic acid detection involving sensors
• C12Q 1/6816 - Hybridisation assays characterised by the detection means
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Abstract

Disclosed herein are compounds that can degrade proteins having an active role in cancer progression, including CK1α (a negative regulator of the canonical Wnt pathway) and WEE1 (a G2/M checkpoint kinase). Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., in the treatment of proliferative diseases such as cancers.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/33 - Heterocyclic compounds

Abstract

Systems and methods of verifying a hardware processing circuit design for a digital system are disclosed. Three different computer models of the same hardware are implemented. The first computer model is implemented on a first sequence of action inputs and a second sequence of action inputs. The second computer model is implemented on the first sequence of action inputs and is allowed to idle until the first sequence is done. The architectural states of the second computer model are then recorded. The third computer model is implemented on the second sequence after having set the third computer model to the recorded architectural states. The outputs of the first computer model and the third computer model are implemented to check for functional consistency. The techniques described herein can be used to check digital designs for functional consistency, are sound and complete, and do not require an understanding of implementation details.

IPC Classes  ?

• G06F 30/33 - Design verification, e.g. functional simulation or model checking
• G06F 115/02 - System on chip [SoC] design

Abstract

Provided herein are compositions, systems, and methods for the generation, identification, and characterization of effector domains for activating and silencing gene expression. In particular, synthetic transcription factors comprising one or more transcriptional activator domains, one or more transcriptional repressor domains, or a combination thereof fused to a heterologous DNA binding domain, and methods of using thereof are provided.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Malaria still afflicts about half of the world population causing more than 400,000 deaths, mostly children. The options for malaria therapy are increasingly becoming limited because of widespread drug resistance. Furthermore, drugs for prophylaxis are suboptimal. This disclosure reports the identification of type II protein kinase inhibitor compounds which have never been explored as antimalarial agents and which now have been discovered to possess therapeutic and prophylactic properties against malaria.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 33/06 - Antimalarials
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

Methods and systems for detecting cell states in a biological sample are disclosed. Methods and systems for predicting a therapeutic response, a severe immune-related adverse event (irAE), a symptomatic irAE, and an irAE grade of a subject to be administered an immunotherapy treatment based on cell states detected from a single biological sample from the subject are also disclosed.

IPC Classes  ?

• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Engineered synthetic signaling molecules, herein termed "trikines", are provided. Trikines are genetically engineered, tri-specific ligands of cell surface receptors, where the trikine specifically binds at high affinity to the extracellular domains of three different cell surface receptor polypeptides. In some embodiments, generation of a receptor multimer by binding to a trikine results in intracellular trans-phosphorylation of receptor subunits. In some embodiments trikines modulate STAT signaling that results from the receptor binding and mutimerization.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07K 14/52 - CytokinesLymphokinesInterferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C07K 19/00 - Hybrid peptides

Abstract

The invention provides compositions and methods for the ex vivo expansion and maintenance of mammalian hematopoietic stem and progenitor cells (HSPCs), including human HSPCs.

IPC Classes  ?

• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C07K 14/52 - CytokinesLymphokinesInterferons

Abstract

An example system for passive sensing includes a coupled pair of resonators including a sensor resonator and a reader resonator, the sensor resonator including a resistor a loss associated with the resistor, and the reader resonator including a MOS cross-coupled pair that implements a nonlinear gain of the reader resonator via compressive saturation of negative resistance. An amplitude detector measures the amplitude of oscillations associated with the reader resonator, and the negative resistance is determined based on the measured amplitude of oscillations associated with the reader resonator when the measured amplitude reaches a steady state, i.e., when the gain of the reader resonator balances the loss of the sensor resonator. The resistance associated with the resistor of the sensor resonator may be determined based on the determined negative resistance. When the resistor is a resistive sensor, indications of measurements by the resistive sensor may be determined in this way.

IPC Classes  ?

• H04Q 9/00 - Arrangements in telecontrol or telemetry systems for selectively calling a substation from a main station, in which substation desired apparatus is selected for applying a control signal thereto or for obtaining measured values therefrom

Abstract

Small molecules compounds and methods of their synthesis are provided. Small molecules identified can inhibit histone acetyltransferase 1 activity. Formulations and medicaments are also provided that are directed to the treatment of human disorders and conditions, such as, for example, neoplasms, cancers, viral, fungal, and parasitic infections, and aging. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.

IPC Classes  ?

• C07D 475/14 - Benz [g] pteridines, e.g. riboflavin
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2

Abstract

Aspects of the present disclosure include polymeric structures having one or more polymeric microneedles. Polymeric structures according to certain embodiments exhibit a macrostructural change (e.g., exhibit elastic deformation) in response to an applied stimulus. In some embodiments. polymeric structures include a microarray of polymeric microneedles for delivering an active agent compound to a subject or for collecting a biological fluid sample from a subject. Methods for applying a polymeric structure having polymeric microneedles to a skin surface of a subject is also described. Methods for making the polymeric structures, such as by high resolution continuous liquid interface production is also provided. Kits having one or more of the subject polymeric structures are also described.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

Systems and methods for clinical neuronavigation in accordance with embodiments of the invention are illustrated. One embodiment includes a method for generating a brain stimulation target, including obtaining functional magnetic resonance imaging (fMRI) image data of a patient's brain, where brain imaging data describes neuronal activations within the patient's brain, determining a brain stimulation target by mapping at least one region of interest to the patient's brain, locating functional subregions within the at least one region of interest based on the fMRI image data, determining functional relationships between at least two brain regions of interest, generating parameters for each functional subregion, generating a target quality score for each functional subregion based on the parameters and selecting a brain stimulation target based on its target quality score and the patient's neurological condition.

IPC Classes  ?

• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61N 2/00 - Magnetotherapy
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
• G01R 33/48 - NMR imaging systems
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/245 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/377 - Electroencephalography [EEG] using evoked responses
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/38 - Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
• A61N 2/00 - Magnetotherapy
• G01R 33/48 - NMR imaging systems
• G06N 20/00 - Machine learning
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Compositions and methods are provided for determining minimal residual disease (MRD) in cancer patients following therapy. In some embodiments the patient is a breast cancer patient that has been treated with NAC. The methods, termed spatial MRS (s-MRD) apply blood-based assessment tools to tumor tissue to accurately characterize molecular residual disease.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6851 - Quantitative amplification
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 30/10 - Sequence alignmentHomology search

Abstract

Systems and methods for state-of-charge estimation in accordance with embodiments of the invention are illustrated. One embodiment includes a battery management system, including a pulse generator configured to provide constant current pulses to a battery, a voltage sensor configured to measure output voltage of the battery, and a state-of-charge monitor, including a processor, and a memory storing a state-of-charge monitoring application that configures the processor to apply a constant current pulse to the battery using the pulse generator, measure the output voltage of the battery in response to constant current pulse, calculate a pulse inverse derivative of a galvanostatic voltage response of the battery, pulse dQ/dV, based on the measured output voltage, estimate a state-of-charge of the battery using the estimated pulse dQ/dV and a complete dQ/dV curve of the battery across a range of state-of-charge of the battery, and provide the estimated state-of-charge.

IPC Classes  ?

• G01R 31/382 - Arrangements for monitoring battery or accumulator variables, e.g. SoC
• G01R 31/396 - Acquisition or processing of data for testing or for monitoring individual cells or groups of cells within a battery
• G01R 31/389 - Measuring internal impedance, internal conductance or related variables
• G01R 31/367 - Software therefor, e.g. for battery testing using modelling or look-up tables
• G01R 31/374 - Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC] with means for correcting the measurement for temperature or ageing

Abstract

Systems and methods for state-of-charge monitoring in accordance with embodiments of the invention are illustrated. One embodiment includes a battery management system including a sine-wave pulse generator configured to provide sine-wave pulses to a battery, a voltage sensor configured to measure output voltage of the battery, and a state-of-charge monitor, including a processor, and a memory storing a state-of-charge monitoring application that configures the processor to apply a sine-wave pulse current to the battery using the sine-wave pulse generator, measure the output voltage of the battery in response to the sine wave pulse current, estimate an impedance of the battery based on the voltage response, estimate a state-of-charge of the battery using the estimated impedance of the battery, and provide the estimated state-of-charge.

IPC Classes  ?

• G01R 31/382 - Arrangements for monitoring battery or accumulator variables, e.g. SoC
• G01R 31/396 - Acquisition or processing of data for testing or for monitoring individual cells or groups of cells within a battery
• G01R 31/389 - Measuring internal impedance, internal conductance or related variables
• G01R 31/367 - Software therefor, e.g. for battery testing using modelling or look-up tables
• G01R 31/374 - Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC] with means for correcting the measurement for temperature or ageing

Abstract

In certain examples, methods and semiconductor structures are directed to devices and methods involving a semiconductor device with a current-blocking layer (CBL) and a first material layer having n-type dopant material that is activated with recovered crystallinity. The CBL may have a surface portion along a plane of the CBL (e.g., in a transistor, the CBL may be between the first material layer and another material layer). A p-type dopant material is located or diffused into the CBL and activated without recovered crystallinity, and the CBL's dopant profile is characterized as corresponding to an outer portion of the CBL with a higher concentration of the p-type dopant material than a concentration of the p-type dopant material in an inner portion of the CBL.

IPC Classes  ?

• H10D 62/80 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials
• H01L 21/385 - Diffusion of impurity materials, e.g. doping materials, electrode materials, into, or out of, a semiconductor body, or between semiconductor regions using diffusion into, or out of, a solid from or into a solid phase, e.g. a doped oxide layer
• H10D 30/01 - Manufacture or treatment
• H10D 30/66 - Vertical DMOS [VDMOS] FETs
• H10D 62/17 - Semiconductor regions connected to electrodes not carrying current to be rectified, amplified or switched, e.g. channel regions

Abstract

Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of TTR and thereby decreasing aggregate formation by TTR. Also disclosed herein are methods to screen for candidate compounds that increase stability of TTR. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.

IPC Classes  ?

• A61K 31/12 - Ketones
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 31/433 - Thiadiazoles
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 487/04 - Ortho-condensed systems
• G01N 21/64 - FluorescencePhosphorescence

Abstract

Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 237/08 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Abstract

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/245 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/377 - Electroencephalography [EEG] using evoked responses
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/38 - Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
• A61N 2/00 - Magnetotherapy
• G01R 33/48 - NMR imaging systems
• G06N 20/00 - Machine learning
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/245 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/377 - Electroencephalography [EEG] using evoked responses
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/38 - Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
• A61N 2/00 - Magnetotherapy
• G01R 33/48 - NMR imaging systems
• G06N 20/00 - Machine learning
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

In one embodiment, a micro-cooler assembly includes a manifold having at least one inlet for receiving a liquid, a plurality of fins, wherein each fin of the plurality of fins includes a micro-channel, and a plurality of vapor gaps interlaced with the plurality of fins. A width of the micro-channels is graded, and/or a width of the vapor gaps is graded. The micro-cooler assembly further includes a cold plate that includes a surface and a wick region disposed on the surface. The manifold is coupled to the surface of the cold plate. The at least one inlet is operable to provide the liquid proximate the wick region. The liquid is operable to be wicked into the wick region through the micro-channels of the plurality of fins, and heating of the liquid changes phase to a vapor that exits the manifold through the plurality of vapor gaps.

IPC Classes  ?

• F28D 15/04 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes with tubes having a capillary structure
• F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
• F28F 3/02 - Elements or assemblies thereof with means for increasing heat-transfer area, e.g. with fins, with recesses, with corrugations
• F28F 3/12 - Elements constructed in the shape of a hollow panel, e.g. with channels

Abstract

in situin situ in permeabilized nuclei, and then tethering chromatin-cleaving or -modifying enzymes. These methods are however limited by their requirement for a nuclear envelope to hold the chromatin together during wash steps and buffer exchanges. This results in large input material requirements due to sample losses, limitations in what types of samples can be processed, increased variability due to handling steps, and an inability to study chromatin outside of its compacted form in the nucleus. A new method for preparing chromatin from cells for downstream genomic chromatin mapping is disclosed. The method uses dilution, precipitation, and dialysis to replace wash steps and buffer exchanges, allowing the entire protocol to take place in a single tube with no removal of material prior to DNA extraction.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6804 - Nucleic acid analysis using immunogens
• C12Q 1/6841 - In situ hybridisation
• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Cells engineered with custom-designed receptors can efficiently transfer membrane-associated macromolecules into recipient cells upon contact, which can be freed from endosomes in recipient cells and optionally functionalized in a trogocytosis-like manner via pH-responsive membrane fusion. A variety of configurations, payload proteins and donor and recipient cells are possible with the methods descried herein.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/86 - Viral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

Devices and methods are provided for closing an incision through fascia or other tissue of a subject. A first closure element is positioned against tissue on a first side of the incision, a second closure element is positioned against tissue on a second side of the incision, and a fastener from or through the first closure element is directed through the tissue and the second closure element to secure the closure elements against the tissue to close the incision.

IPC Classes  ?

• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

Provided herein is a combination comprising: an optically transparent substrate, a sample that comprises biological analytes, and a layer of a conductive organic polymer. In this combination, the layer of polymer may be between the sample and the substrate, the layer of polymer may coat the section on the opposite side to the substrate, or both. The method comprises a liquid composition, wherein the composition comprises PEDOT, PSS, DMS02 and an organic solvent or polyaniline (emeraldine salt), DMS02 and an organic solvent; and wherein the applying comprises spraying, spin coating or spreading a composition comprising a solvent and the polymer on the surface of the substrate and then removing the solvent by evaporation. Methods of analyzing the sample in this combination are also provided.

IPC Classes  ?

• C09D 165/00 - Coating compositions based on macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chainCoating compositions based on derivatives of such polymers
• C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
• C08G 73/02 - Polyamines
• C09D 179/02 - Polyamines
• G01N 1/30 - StainingImpregnating
• H01B 1/12 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances organic substances

Abstract

Methods are disclosed for predicting a likelihood of developing a severe immune-related adverse event (irAE) associated with the administration of an immunotherapy in a melanoma patient based on abundances of activated CD4 memory T cells and/or diversities of T cell receptors (TCR) within a peripheral blood sample obtained from the patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Aspects of the present disclosure include methods for making a polymeric structure having one or more microchannels. Methods according to certain embodiments include conveying a polymerizable composition through a conduit into a space between a build elevator and a build surface of a liquid interface production module, irradiating the polymerizable composition positioned between the build elevator and the build surface to generate a polymerizable composition having a first polymerized region of the polymerizable composition having a microchannel in contact with the build elevator and a first non-polymerized region of the polymerizable composition in contact with the build surface, displacing the build elevator away from the build surface, irradiating the first non-polymerized region of the polymerizable composition to generate a second polymerized region of the polymerizable composition in contact with the first polymerized region and a second non-polymerized region in contact with the build surface and repeating one or more steps in a manner sufficient to generate a polymeric structure having one or more microchannels positioned within the polymeric structure. Systems having a conduit for conveying a polymerizable composition to a liquid interface polymerization module having a build elevator and a build surface configured are also described. Polymer structures having a predetermined fluidic microchannel network prepared by the subject methods and non-transitory computer readable storage medium for practicing the subject methods are also provided.

IPC Classes  ?

• B29C 64/336 - Feeding of two or more materials
• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
• B29C 64/205 - Means for applying layers
• B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes

Abstract

There are provided herein, inter alia, complexes, compositions and methods for the delivery of nucleic acid into a cell in vivo. The complexes, compositions and methods may facilitate complexation, protection, delivery and release of oligonucleotides and polyanionic cargos into target cells, tissues, and organs both in vitro and in vivo.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

Devices are provided for performing endovascular surgical procedures. In one example, the device includes a magnetically actuated untethered rotation device, i.e., a magnetic spinner, that can navigate in blood vessels through its spinning-enabled propulsion. The magnetic spinner is capable of providing suction, shear force, carrying load for functions including navigation in multi-branched blood vessels, e.g., for targeted drug delivery, treating brain aneurysm, mechanical thrombectomy, rotablation for plaque removal, and the like.

IPC Classes  ?

• A61B 17/3207 - Atherectomy devices
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

Optical spectroscopy based on adsorption of a sample on a surface of a mechanical resonator is provided. The sample is illuminated with light that is intensity modulated at or near the resonance frequency of a mode of the mechanical resonator. Thermal expansion caused by optical absorption at the sample effectively generates a force on the mechanical resonator that excites the resonant mode of the resonator. Thus a measurement of displacement or the like of the mechanical resonator (e.g., via the piezoelectric effect) provides the desired spectroscopic signal. Spectra can be obtained by sweeping a wavelength of the optical source or by using an optical dual-comb source having multiple emission wavelengths each intensity modulated at a different frequency.

IPC Classes  ?

• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry

Abstract

Systems and methods for expression and delivery of proteinaceous species are described. Generally, a system can comprise biological cells within a porous membrane. The biological cells can be utilized to produce proteinaceous species. The biological cells can further store proteinaceous species within secretory granules such that the species can be controllably released upon depolarization of the cell. A secondary force can be provided to release proteinaceous species out of the porous membrane. Proteinaceous species can be expressed from an expression cassette configured to provide controllable release.

IPC Classes  ?

• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61K 9/50 - Microcapsules
• A61K 35/39 - PancreasIslets of Langerhans
• A61K 38/26 - Glucagons
• A61K 38/28 - Insulins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

In one example, a semiconductor has a set of one or more scaffolding tiers, each tier of the set of one or more scaffolding tiers including a stack of material layers. The stacked layers include: a device layer in which at least one hot-spot region is located; a thin poly crystalline diamond (PCD) layer, located between the device layer and a thick layer, thermally coupled to said at least one hot-spot region of the device layer; and the thick layer has a plurality of diamond vias, providing respective thermal pathways, with diamond-via end portions that are thermally coupled to the PCD layer. The thick layer includes elongated diamond-filled thermal-pathway vias having end portions thermally coupled to the PCD layer for enabling thermal energy to flow from said at least one hot-spot region into and/or through the thick layer.

IPC Classes  ?

• H01L 23/373 - Cooling facilitated by selection of materials for the device
• H01L 29/20 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIIBV compounds
• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
• H01L 23/48 - Arrangements for conducting electric current to or from the solid state body in operation, e.g. leads or terminal arrangements

Abstract

Compositions comprising a therapeutic agent that induces a long QT interval and a cardioprotective agent are provided. Use of the compositions in managing risk of or actual QT prolongation are described, where the cardioprotective agent is administered before, during and/or after the therapeutic agent that induces a long QT interval.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• A61P 9/06 - Antiarrhythmics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

The present invention provides a clinically applicable method of hematopoietic stem cell transplantation using antibody-based immunosuppression, which can enable engraftment of hematopoietic stem cells. In particular, in Fanconi Anemia this treatment alone is sufficient to enable engraftment of allogeneic hematopoietic stem cells, even in mismatched settings. The methods are optionally combined with CD117 mAb conditioning.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)

Abstract

Compositions, methods, and kits are provided for treating bacterial infections with nanoclusters comprising a metallic core conjugated to a nucleotide. Recalcitrant infections are often difficult to treat because of the presence of persister cells, a subpopulation of bacterial cells that is highly tolerant of traditional antibiotics. Persister cells are dormant, which makes them less susceptible to many antibiotics, which are designed to kill growing cells. Administration of nanoclusters comprising a nucleotide was found to be highly efficacious in eradicating persister cells and for treating infections for a broad range of bacterial species, including Gram-positive and Gram-negative bacteria. Such treatment was effective not only in eradicating planktonic bacteria but also bacteria in biofilms.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 33/242 - GoldCompounds thereof
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 31/04 - Antibacterial agents

Abstract

Differential methylation profiles of a panel of genes are identified from colorectal carcinoma tissues of colorectal cancer patients compared to normal colon mucosal tissue or to white blood cells from healthy subjects. A high methylation level of cytosines at CpG dinucleotide sites (in CpG-rich regions) of the panel of genetic loci are further validated in plasma cell-free DNA as signature markers indicative of colorectal cancer, which is useful for early stage detection of colorectal cancer and monitoring of disease progression. This panel of genetic loci include genes MAP3K14-AS1, DNM1P46, EMBP1, GATM, VSV2, LAYN, and SFMBT2, which individually or in combination can complement SEPT9-based assays in improving sensitivity and/or specificity in the detection of colorectal cancer. Assay methods and reagents for detection of the presence and levels of methylation of the marker genetic loci are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6869 - Methods for sequencing